Annual report pursuant to Section 13 and 15(d)

Intangible Assets and Impairment of Long-Lived Assets (Tables)

v3.23.1
Intangible Assets and Impairment of Long-Lived Assets (Tables)
12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
    Remaining
Amortization
Period
  As of December 31, 2022     As of December 31, 2021  
    in Years at
December 31,
2022
  Gross
Asset
Value
    Accumulated
Amortization
    Net
Carrying
Value
    Gross
Asset
Value
    Accumulated
Amortization
    Net
Carrying
Value
 
Licensed patents   13.5   $ 596,259     $ (142,654 )   $ 453,605     $ 603,919     $ (110,759 )   $ 493,160  
Technology license   16.6     1,485,159       (279,906 )     1,205,253       1,658,550       (202,797 )     1,455,753  
        $ 2,081,418     $ (422,560 )   $ 1,658,858     $ 2,262,469     $ (313,556 )   $ 1,948,913  

 

Schedule of future amortization related to intangible assets
For the Years Ending December 31,      
2023   $ 109,489  
2024     109,489  
2025     109,489  
2026     109,489  
2027     109,489  
Thereafter     1,111,413  
    $ 1,658,858  

 

Schedule of goodwill activity
    CBR
Pharma
Goodwill
    180 LP
Goodwill
    Consolidated
Goodwill
 
Balance, December 31, 2021   $ 23,749,631     $ 13,238,255     $ 36,987,886  
Currency translation     (664,353 )    
-
      (664,353 )
                         
Balance, March 31, 2022     23,085,278       13,238,255       36,323,533  
Currency translation     (1,734,582 )    
-
      (1,734,582 )
                         
Balance, June 30, 2022     21,350,696       13,238,255       34,588,951  
Currency translation     (1,750,386 )    
-
      (1,750,386 )
Balance before impairment     19,600,310       13,238,255       32,838,565  
Impairment of goodwill     (11,264,612 )     (7,608,238 )     (18,872,850 )
                         
Balance, September 30, 2022     8,335,698       5,630,017       13,965,715  
Currency translation     708,713      
-
      708,713  
Balance before impairment     9,044,411       5,630,017       14,674,428  
Impairment of goodwill     (9,044,411 )     (5,630,017 )     (14,674,428 )
                         
Balance, December 31, 2022   $
-
    $
-
    $
-
 

 

    CBR
Pharma IP
R&D Assets
    180 LP IP
R&D
Assets
    Consolidated
IP R&D
Assets
 
Balance, December 31, 2021   $ 1,632,780     $ 10,943,000     $ 12,575,780  
Currency translation     (45,674 )    
-
      (45,674 )
                         
Balance, March 31, 2022     1,587,106       10,943,000       12,530,106  
Currency translation     (119,252 )    
-
      (119,252 )
                         
Balance, June 30, 2022     1,467,854       10,943,000       12,410,854  
Currency translation     (120,338 )    
-
      (120,338 )
                         
Balance, September 30, 2022     1,347,516       10,943,000       12,290,516  
Currency translation     114,568      
-
      114,568  
Balance before impairment     1,462,084       10,943,000       12,405,084  
Impairment of IP R&D assets     (1,462,084 )     (1,880,000 )     (3,342,084 )
                         
Balance, December 31, 2022   $
-
    $ 9,063,000     $ 9,063,000